Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.

Revenue
+34.1%
EPS
+34.4%
Free cash flow
−85.8%
Total debt
−0.06%

Quarter to September 2026, against a year earlier

365.77 25.26 −6.46%
Market cap
$52.4B
P/E
0.0×
Fwd P/E
−289×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a

Natera, Inc. (NTRA) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Natera, Inc. (NTRA) trades at a P/S ratio of 18.1×. Over the past ten years it has ranged from 0.3× (September 2015) to 25.8× (February 2021); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 13.6× 16.74%
FY2024 11.6× 76.88%
FY2023 6.6× 42.43%
FY2022 4.6× (65.85%)
FY2021 13.5× (34.43%)
FY2020 20.6× 166.02%
FY2019 7.8× 147.29%
FY2018 3.1× 30.14%
FY2017 2.4× (16.54%)
FY2016 2.9× 94.10%

Quarterly newest first

Period P/S ratio Change
Sep 2026 20.5× 42.48%
Jun 2026 14.4× 26.97%
Mar 2026 11.3× (16.69%)
Dec 2025 13.6× 30.18%
43 more quarters

Against its own ten years

Low 0.3× High 25.8×
Ten-year median 6.7×
Current reading's percentile 90

P/S ratio against peers

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on NTRA